Trending...
- LS2 Partners with Angels Of Dirt's "Next Chapter Racer" Series Celebrating Women and Girls in Motorsports
- Everything Policy Unveils Their Classroom Resources Behind Every Policy Topic
- Timbrana Helps General Contractors Improve Jobsite Visibility and Subcontractor Accountability
Single ~ CS Genetics, a leading company in next-generation single-cell genomics, has announced the launch of their latest product, the SimpleCell™ 3' Gene Expression kits. This is the company's first commercial offering and is designed to make single-cell transcriptomics more accessible and scalable.
The SimpleCell™ platform utilizes Kinetic Confinement, a revolutionary molecular process, to provide an instrument-free and scalable solution for single-cell genomics. This technology has been in development for several years and is now being released commercially.
Luke Edelman, Founder and Chief Technology Officer at CS Genetics, expressed his excitement about the launch of SimpleCell™. He stated, "After several years of development, we are so excited to be releasing our first SimpleCell™ products commercially. Single cell is a very important and impactful modality for biological measurement, and we feel strongly that a diverse ecosystem of technology platforms – now including Kinetic Confinement and SimpleCell™ – is good for the field and for the cadence of discovery."
More on The PennZone
The SimpleCell™ 3' Gene Expression kits have several key features that make them stand out in the market. These include a single-day cells-to-sequencer workflow using standard lab equipment and pipetting, cost-effectiveness at under $500 per sample regardless of experiment scale or purchase volume, and compatibility with various sample types such as blood/PBMCs, cell lines, disaggregated solid tissues, and more.
CS Genetics will be showcasing details about Kinetic Confinement technology and the SimpleCell™ product line at the 2024 Annual Meeting of the American Society for Human Genetics in Denver. Attendees can visit CS Genetics at booth 402 or join the SimpleCell™ CoLab talk on Wednesday, November 6th at 4:00 PM in Theater 3 to learn more about the future of single-cell genomics.
Early customers of SimpleCell™ have already expressed their satisfaction with the product. Charlly Kao, Principal Scientist at the Center for Applied Genomics (CAG) at the Children's Hospital of Philadelphia, shared, "We've been eagerly waiting for something like SimpleCell™ that can perform single-cell transcriptome profiling in a flexible, instrument-free, and simple-to-use workflow at a more attractive price point."
More on The PennZone
Hákon Hákonarson, Director of the Center for Applied Genomics at the Children's Hospital of Philadelphia and Professor of Pediatrics at the Perelman School of Medicine, also commented on the potential impact of SimpleCell™. He said, "Kinetic Confinement and the SimpleCell™ platform are timely new additions to the single cell universe. As a translational research facility with access to a very large number of clinical specimens, we are particularly excited about the opportunities presented by the platform to enable significantly larger-scale single cell studies than has been realistically possible with other tools."
Yuriy Alekseyev, director of the Single Cell and NGS core laboratory at Boston University Chobanian & Avedisian School of Medicine, also praised SimpleCell™ for its affordability and ease-of-use. He stated, "SimpleCell™ checks these boxes well. It's simple to set up, cost-effective, and a welcome addition for users who've been looking for a platform that doesn't require a huge learning curve or large costs for each experiment."
The SimpleCell™ 3' Gene Expression kits are available in 8-sample and 16-sample sizes and can now be ordered for shipment across the U.S., U.K., Europe, and select global regions through CS Genetics' website. To learn more about this innovative product or to place an order, visit www.csgenetics.com.
The SimpleCell™ platform utilizes Kinetic Confinement, a revolutionary molecular process, to provide an instrument-free and scalable solution for single-cell genomics. This technology has been in development for several years and is now being released commercially.
Luke Edelman, Founder and Chief Technology Officer at CS Genetics, expressed his excitement about the launch of SimpleCell™. He stated, "After several years of development, we are so excited to be releasing our first SimpleCell™ products commercially. Single cell is a very important and impactful modality for biological measurement, and we feel strongly that a diverse ecosystem of technology platforms – now including Kinetic Confinement and SimpleCell™ – is good for the field and for the cadence of discovery."
More on The PennZone
- Ashley Russo Receives Linny Lifetime Achievement Award
- How to Choose a Heating Repair Company in Philadelphia
- Renew Integrative Health Publishes Updated Peptide Therapy Guide to Help Patients Understand Their Options
- Lehigh County Drug and Alcohol Celebrates Grand Opening of Journeys
- Timbrana Addresses the Missing Follow-Through in Commercial Construction Projects
The SimpleCell™ 3' Gene Expression kits have several key features that make them stand out in the market. These include a single-day cells-to-sequencer workflow using standard lab equipment and pipetting, cost-effectiveness at under $500 per sample regardless of experiment scale or purchase volume, and compatibility with various sample types such as blood/PBMCs, cell lines, disaggregated solid tissues, and more.
CS Genetics will be showcasing details about Kinetic Confinement technology and the SimpleCell™ product line at the 2024 Annual Meeting of the American Society for Human Genetics in Denver. Attendees can visit CS Genetics at booth 402 or join the SimpleCell™ CoLab talk on Wednesday, November 6th at 4:00 PM in Theater 3 to learn more about the future of single-cell genomics.
Early customers of SimpleCell™ have already expressed their satisfaction with the product. Charlly Kao, Principal Scientist at the Center for Applied Genomics (CAG) at the Children's Hospital of Philadelphia, shared, "We've been eagerly waiting for something like SimpleCell™ that can perform single-cell transcriptome profiling in a flexible, instrument-free, and simple-to-use workflow at a more attractive price point."
More on The PennZone
- AI Agents Are Getting Their Own Computers. HRTech Leading in Vertical Harness Development
- UK Financial Ltd Announces Two-for-One Upgrade of Maya 3 to Maya 3G Token Using Chainlink Cross-Chain Technology
- JKS Financial Gives Back Through Light of Life Rescue Mission Food Pantry
- Critical FDA Milestone much Closer as Preservative-Free Ketamine Review Advances: NRx Pharmaceuticals (N A S D A Q: NRXP)
- Corner Property Management AAMC Expands Presence with Clover Mill Management Agreement
Hákon Hákonarson, Director of the Center for Applied Genomics at the Children's Hospital of Philadelphia and Professor of Pediatrics at the Perelman School of Medicine, also commented on the potential impact of SimpleCell™. He said, "Kinetic Confinement and the SimpleCell™ platform are timely new additions to the single cell universe. As a translational research facility with access to a very large number of clinical specimens, we are particularly excited about the opportunities presented by the platform to enable significantly larger-scale single cell studies than has been realistically possible with other tools."
Yuriy Alekseyev, director of the Single Cell and NGS core laboratory at Boston University Chobanian & Avedisian School of Medicine, also praised SimpleCell™ for its affordability and ease-of-use. He stated, "SimpleCell™ checks these boxes well. It's simple to set up, cost-effective, and a welcome addition for users who've been looking for a platform that doesn't require a huge learning curve or large costs for each experiment."
The SimpleCell™ 3' Gene Expression kits are available in 8-sample and 16-sample sizes and can now be ordered for shipment across the U.S., U.K., Europe, and select global regions through CS Genetics' website. To learn more about this innovative product or to place an order, visit www.csgenetics.com.
0 Comments
Latest on The PennZone
- Creole101 Launches Multilingual Dictionary App with 50,000+ Entries, Vocabulary Games and Haitian Cultural Resources
- Hilton Waikiki Beach Resort & Spa Introduces Level 37 Sky Lounge by Casamigos
- Self-Published Dad's Santa Book Finally Found After 3 Years on Amazon
- Meta Partnership Expanding as Omni One Orders Surge 3X -New Consumer Bundles, Defense Opportunities & AI Robotics: Virtuix Holdings: N A S D A Q: VTIX
- Roots for Boots to Participate in 2026 Adams County Community Foundation Giving Spree
- Timbrana Helps General Contractors Improve Jobsite Visibility and Subcontractor Accountability
- Citizens for West Virginia Election Integrity Urges "FOR" on Amendment 1
- Vegan Kingz Expands Direct-Import Wholesale Lineup to Help Commercial Kitchens Cut Ingredient Costs
- Acuvance Survey Finds ERP Integration Remains a Key Challenge as Healthcare Organizations Prepare for AI
- Everything Policy Unveils Their Classroom Resources Behind Every Policy Topic
- Constantine "Costa" Kapothanasis II Acquires The Lubri-Loy Company, Carrying a 77-Year-Old American Lubricant Brand Into Its Next Era
- LS2 Partners with Angels Of Dirt's "Next Chapter Racer" Series Celebrating Women and Girls in Motorsports
- Danish company biosuite introduces biotech procurement software to track outsourced R&D commitments
- Ten Ten Ten Announces Alento, Its Initiative to Help Independent Primary Care Thrive
- JFAB Consulting to Celebrate New Brand with Private VIP Event at Acrisure Stadium
- Industrial & systems engineering educator and professional to lead global strategic partnerships for professional society
- Convergence of AI, Wearable Technology, Remote Patient Monitoring and Real-World Healthcare: PomDoctor Ltd. (N A S D A Q: POM)
- Timbrana — Construction Project Awareness Software for General Contractors
- Service Guys Urges Ontario Homeowners to Book Chimney Cleaning and WETT Inspections Before the 2026 Heating Season
- WOWX Completes Its Transition from CEX to Decentralized Derivatives Infrastructure